Posaconazole Patent Expiration
Posaconazole is used for preventing and treating fungal infections in severely immunocompromised patients aged 2 years and older. It was first introduced by Schering Corp
Posaconazole Patents
Given below is the list of patents protecting Posaconazole, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Noxafil | US9493582 | Alkylated cyclodextrin compositions and processes for preparing and using the same | Feb 27, 2033 | Merck Sharp Dohme |
| Noxafil | US9023790 | Posaconazole intravenous solution formulations stabilized by substituted β-cyclodextrin | Jul 04, 2031 | Merck Sharp Dohme |
| Noxafil | US9358297 | Posaconazole intravenous solution formulations stabilized by substituted β-cyclodextrin | Jun 24, 2031 | Merck Sharp Dohme |
| Noxafil | US10117951 | Sulfoalkyl ether cyclodextrin compositions | Mar 13, 2029 | Merck Sharp Dohme |
| Noxafil | US8410077 | Sulfoalkyl ether cyclodextrin compositions | Mar 13, 2029 | Merck Sharp Dohme |
| Noxafil | US9750822 | Sulfoalkyl ether cyclodextrin compositions | Mar 13, 2029 | Merck Sharp Dohme |
| Noxafil | US8263600 | Antifungal composition with enhanced bioavailability |
Apr 01, 2022
(Expired) | Schering |
| Noxafil | US5661151 | Tetrahydrofuran antifungals |
Jul 19, 2019
(Expired) | Schering |
| Noxafil | US5661151 | Tetrahydrofuran antifungals |
Jul 19, 2019
(Expired) | Merck Sharp Dohme |
| Noxafil | US6958337 | Crystalline antifungal polymorph |
Oct 05, 2018
(Expired) | Schering |
| Noxafil | US5703079 | Tetrahydrofuran antifungals |
Aug 26, 2014
(Expired) | Schering |
| Noxafil | US5703079 | Tetrahydrofuran antifungals |
Aug 26, 2014
(Expired) | Merck Sharp Dohme |
Posaconazole's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Posaconazole:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Phase 1 Open-label Study of AMX-883 Alone in Participants With AML and High-risk MDS and in Combination in Participants With AML | Amphista Therapeutics Ltd | NA |
RECRUITING
(Sep 1, 2026)
| PHASE1 |
| Posaconazole (MK-5592) Intravenous and Oral in Children (<2 Years) With Invasive Fungal Infection (MK-5592-127) | Merck Sharp & Dohme LLC | NA |
RECRUITING
(Jul 1, 2026)
| PHASE2 |
| Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression | AstraZeneca | NA |
RECRUITING
(Jul 1, 2026)
| PHASE1, PHASE2 |
| A Study to Evaluate S241656 Alone or in Combination in Participants With Selected Myeloid Malignancies | Servier | NA |
NOT YET RECRUITING
(Jul 1, 2026)
| PHASE1, PHASE2 |